CTLA4 and neoplasm: The main groups of Mabs in SCC therapy are Mabs targeting EGFR, HER2, HGF, and VEGF, alongside checkpoint inhibitors (including Mabs to PD‐1, CTLA4, and NKG2A) and tumor targeting Mabs.